Results 61 to 70 of about 174,911 (201)

Subacute Combined Degeneration and Acute Pulmonary Embolism Caused by Nitrous Oxide–Induced Vitamin B12 Deficiency

open access: yesAnnals of Internal Medicine: Clinical Cases
Nitrous oxide (NO) misuse is an underrecognized cause of vitamin B12 deficiency. Patients may present with paresthesia, ataxia, cognitive and behavioral changes, macrocytic anemia, and thromboembolism.
Syeda Fatima   +4 more
doaj   +1 more source

Repeated Response to Daratumumab in Refractory MGUS‐Associated Pure Red Cell Aplasia Persisting After Allogeneic Transplantation: A Case Report

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Pure red cell aplasia (PRCA) is usually managed as a disorder driven predominantly by cellular immune mechanisms, but plasma cell‐directed therapy may be relevant in selected cases associated with monoclonal gammopathy. We report a case of refractory PRCA associated with IgG‐kappa monoclonal gammopathy of undetermined significance (MGUS). A 64‐
Kyoko Yoshihara   +9 more
wiley   +1 more source

Differential diagnosis of macrocytic anemias - literature review [PDF]

open access: yes, 2018
Author: Zdeněk Kepka Thesis title: Differential diagnosis of macrocytic anemias - literature review Type of assignment: Bachelor's thesis Charles University, Faculty of Pharmacy in Hradec Králové Branch of study: Healthcare Laboratory Assistant (ZDLB ...
Kepka, Zdeněk
core  

Macrocytic anemia (pernicious type) observed in dog

open access: yes, 1952
É descrito em cão um caso, que o A. supõe de anemia macrocítica perniciosa, caracterizado por sintomatologia nervosa e cardiovascular, leucopenia, aumento do volume corpuscular médio e da hemoglobina corpuscular média índice de côr e de volume acima de 1,
Migliano, Max Ferreira
core   +1 more source

Etiological Profile of Macrocytic Anemia in Patients Presenting to a Tertiary Care Hospital

open access: yesAssam Journal of Internal Medicine
Background: Macrocytic anemia is a common hematological finding with a wide range of causes, from nutritional deficiencies to systemic illnesses and bone marrow disorders.
Akhila Nampally   +2 more
doaj   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

open access: yesBritish Journal of Haematology, Volume 209, Issue 4, Page 1469-1481, October 2026.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi   +3 more
wiley   +1 more source

Etiological Profile of Macrocytic Anemia in Patients Admitted in PSG Hospitals [PDF]

open access: yes, 2015
INTRODUCTION: Macrocytosis is common in various clinical settings and it is found in approximately 1.7–3.6% of people admitted for care for any cause1,2,3. Macrocytosis would be seen even in the absence of anemia. Heterogeneous group of disorders acting
Yoganathan, C
core  

A stepwise diagnostic approach for undiagnosed Anemia in children: A model for low-middle income country

open access: yes, 2023
Background: Reaching a precise diagnosis in rare inherited anemia is extremely difficult and challenging, especially in areas with limited use of genetic studies, which makes undiagnosed anemia a unique clinical entity in tertiary hematology centers.
Ragab I. A.   +7 more
core   +1 more source

Beyond Hemoglobin Levels: Integrating Anemia Phenotyping Into Prognostic Models for Patients With Stroke Following Intravenous Thrombolysis

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Anemia predicts poor outcomes after intravenous thrombolysis in acute ischemic stroke. Whether morphological anemia subtypes differentially affect prognosis remains unclear.
Senwei Tan   +11 more
doaj   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima   +48 more
wiley   +1 more source

Home - About - Disclaimer - Privacy